Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  4Sc AG    VSC   DE000A14KL72

4SC AG (VSC)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
6.75(c) 6.7(c) 7.42(c) 7.8(c) 8.37(c) Last
100 001 35 282 178 760 144 504 155 928 Volume
+0.60% -0.74% +10.75% +5.12% +7.31% Change
More quotes
Financials (€)
Sales 2017 5,20 M
EBIT 2017 -12,7 M
Net income 2017 -12,0 M
Finance 2017 40,2 M
Yield 2017 -
Sales 2018 4,95 M
EBIT 2018 -14,5 M
Net income 2018 -13,8 M
Finance 2018 27,9 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 41,6x
EV / Sales2018 46,2x
Capitalization 257 M
More Financials
Company
4SC AG engages in the development of small molecule drugs that targets cancer through epigenetic mechanisms.It also involves in the preclinical and clinical development of its products.Its assets are resminostat, 4SC-202, and 4SC-208.The company was founded by Ulrich Dauer, Daniel Vitt, Stefan... 
More about the company
Surperformance© ratings of 4Sc AG
Trading Rating : - Investor Rating :
More Ratings
Latest news on 4SC AG
01/314SC : Positive DSMB safety review of 4SC's pivotal RESMAIN study of resminostat ..
EQ
01/224SC : strengthens patent protection for its Hedgehog/GLI signaling inhibitor 4SC..
EQ
01/094SC AG : 11 upcoming conferences and investor events
EQ
20174SC : receives Pediatric Investigation Plan Waiver for resminostat in CTCL from ..
EQ
20174SC AG : Preliminary announcement of the publication of financial reports accord..
EQ
20174SC AG : Release according to Article 26, Section 1 of the WpHG [the German Secu..
EQ
20174SC : receives milestone payment from Immunic
EQ
20174SC AG : Significant milestone reached for pivotal RESMAIN study of resminostat ..
EQ
20174SC AG : Notification and public disclosure of transactions by persons
EQ
20174SC AG : Notification and public disclosure of transactions by persons
EQ
More news
Sector news : Biotechnology & Medical Research - NEC
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/31Positive DSMB safety review of 4SC's pivotal RESMAIN study of resminostat in .. 
01/224SC AG strengthens patent protection for its Hedgehog/GLI signaling inhibitor..
1
01/094SC AG: 11 upcoming conferences and investor events  
01/094SC AG: 11 upcoming conferences and investor events  
20174SC : receives Pediatric Investigation Plan Waiver for resminostat in CTCL fr.. 
More tweets
Qtime:40
News from SeekingAlpha
02/064SC (FSCGF) Presents At BioCapital Europe 2018 - Slideshow 
02/033 THINGS IN BIOTECH YOU SHOULD LEARN : February 2, 2018 
20164SC AG Presents at The German Equity Forum 2016 
Chart 4SC AG
Duration : Period :
4Sc AG Technical Analysis Chart | VSC | DE000A14KL72 | 4-Traders
Technical analysis trends 4SC AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 3,50 €
Spread / Average Target -58%
EPS Revisions
Managers
NameTitle
Jason Loveridge Chairman-Management Board & CEO
Clemens M. Doppler Chairman-Supervisory Board
Susanne Danhauser-Riedl Chief Medical Officer
Roland Baumgartner Chief Scientific Officer
Manfred Rüdiger Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
4SC AG57.16%285
CELLTRION, INC.--.--%36 110
IQVIA HOLDINGS INC6.93%21 125
LONZA GROUP-7.82%18 606
INCYTE CORPORATION-6.91%18 063
NEKTAR THERAPEUTICS40.66%13 227